case_images: PMC11063249_01
case_images: Patient's clinical progression and radiologic response to brigatinib plus entrectinib therapy. (A) Schematic overview of clinical progression. (B) Pulmonary and (C) liver computed tomography findings: pre-treatment (Sep 2022) and 2 months post-treatment (Nov 2022), 5 months post-treatment (Feb 2023), and 8 months post-treatment (May 2023) with brigatinib plus entrectinib. PFS, progression-free survival.
case_images: fonc-14-1339511-g001.jpg
case_images: PMC11063249_01_fonc-14-1339511-g001.jpg
case_images: f1
case_images: The patient was treated with frontline alectinib, achieving a best response of partial response (PR) ( Figure 1A ). According to the RECIST v1.1 criteria, these findings collectively indicate progressive disease (PD), with the patient achieving a progression-free survival (PFS) of 19 months ( Figure 1A ). A pathological analysis of a liver biopsy verified the presence of metastatic adenocarcinoma ( Figures 1B, C ). The liver biopsy sample contains 50% normal liver tissue and 50% metastasized lung cancer tissue ( Supplementary Figure S1 ). A follow-up CT evaluation conducted two months after initiating this combination therapy revealed significant improvement in both pulmonary and liver lesions, indicative of a PR ( Figures 1B, C ).
case_images: Detection of ETV6-NTRK3 fusion following progression on fourth line brigatinib plus chemotherapy. (A) Integrative Genomics Viewer (IGV) snapshot of the fusion. (B) Diagram illustration of the chimeric protein generated.
case_images: fonc-14-1339511-g002.jpg
case_images: PMC11063249_01_fonc-14-1339511-g002.jpg
case_images: f2
case_images: The variant frequencies of these fusions were 23.4% in the tumor tissue and 24.1% in the plasma, respectively, as shown in  Figure 2 .